fig
rankl
opg
express
chikvinfect
joint
chikungunya
viru
chikv
mosquitotransmit
alphaviru
caus
sever
acut
chronic
polyarthr
chikv
first
isol
tanzania
viru
emerg
rapidli
last
decad
caus
outbreak
island
indian
ocean
southern
europ
southeast
asia
chikv
spread
western
hemispher
end
infect
million
peopl
north
america
central
america
south
america
acut
symptom
chikv
infect
includ
fever
rash
typic
resolv
within
day
joint
muscl
pain
chikv
arthritogen
alphavirus
directli
invad
synovium
caus
inflammatori
arthriti
character
articular
swell
prolong
morn
stiff
chikvinduc
arthriti
human
persist
mani
individu
progress
chronic
diseas
last
month
year
epidemiolog
project
suggest
current
individu
western
hemispher
chronic
chikv
arthriti
chronic
chikv
arthriti
clinic
similar
seroneg
rheumatoid
arthriti
ra
autoimmun
diseas
character
symmetr
joint
pain
swell
morn
stiff
treatment
newer
diseasemodifi
antirheumat
drug
dmard
effect
prevent
bone
eros
deform
seen
patient
untreat
ra
whether
chronic
chikv
arthriti
caus
eros
diseas
remain
controversi
although
report
bone
eros
patient
infect
chikv
effect
treatment
ra
reli
earli
diagnosi
eros
occur
within
month
onset
diseas
chikv
ra
exhibit
signific
clinic
overlap
potenti
confus
diagnos
inadvert
treat
chikv
arthriti
dmard
therapi
receptor
biolog
dmard
block
cell
costimul
deplet
b
cell
among
newest
drug
use
treat
ra
tofacitinib
oral
dmard
inhibit
jak
janu
kinas
stat
signal
transduc
activ
transcript
signal
broadli
blunt
cytokin
respons
howev
mani
dmard
virtu
immunosuppress
properti
may
predispos
seriou
microbi
infect
thu
need
determin
whether
dmard
effect
benign
deleteri
treatment
chikv
arthriti
current
standard
care
chikv
arthriti
treatment
nonsteroid
antiinflammatori
drug
nsaid
although
often
amelior
symptom
one
trial
compar
chloroquin
dmard
meloxicam
nsaid
found
differ
efficaci
although
placebo
group
includ
trial
design
anoth
openlabel
studi
examin
combin
hydroxychloroquin
methotrex
treatment
chikv
arthriti
found
patient
partial
respond
therapi
although
patient
achiev
signific
improv
diseas
score
subcutan
inocul
young
wildtyp
wt
immunocompet
mice
pathogen
strain
chikv
result
acut
foot
swell
myositi
arthriti
model
swell
resolv
within
first
week
infect
although
mild
chronic
diseas
observ
histolog
week
month
find
contrast
diseas
human
natur
host
frequent
protract
clinic
diseas
cours
human
patient
chikv
arthriti
increas
number
circul
activ
cytolyt
cell
patient
untreat
ra
gene
express
signatur
observ
mous
model
chikv
arthriti
ra
suggest
overlap
contribut
cellassoci
pathway
diseas
mice
lack
deplet
tcell
reduc
foot
swell
arthriti
acut
chikv
infect
suggest
cell
contribut
patholog
arthriti
inflammatori
monocyt
also
thought
play
initi
role
chikv
arthriti
mice
inhibit
product
monocyt
chemoattract
bindarit
improv
diseas
final
treatment
mice
antichikv
monoclon
antibodi
mab
day
infect
prevent
arthriti
whether
therapi
infect
effect
studi
moreov
previou
studi
test
efficaci
clinic
avail
dmard
chikv
arthriti
mice
examin
efficaci
sever
us
food
drug
administr
fda
approv
ra
therapi
mous
model
chikv
infect
identifi
two
dmard
tofacitinib
efficaci
acut
chikv
arthriti
particular
pair
neutral
antichikv
human
mab
highli
effect
reduc
joint
inflamm
periarticular
swell
migrat
inflammatori
leukocyt
infect
even
administ
sever
day
viru
inocul
thu
combin
antiinflammatori
antibodybas
antivir
therapi
may
serv
model
treat
human
arthriti
caus
chikv
relat
virus
basi
previou
data
show
immun
cell
proinflammatori
cytokin
contribut
chikv
arthriti
mice
studi
show
chikv
arthriti
clinic
mimic
seroneg
ra
hypothes
exist
fdaapprov
therapi
ra
might
amelior
acut
chikv
arthriti
test
idea
perform
multiarm
prospect
studi
fig
inocul
wt
mice
subcutan
left
rear
foot
focusform
unit
ffu
pathogen
clinic
isol
chikv
la
reunion
mice
divid
group
anim
receiv
one
follow
treatment
begin
day
infect
methylprednisolon
naproxen
methotrex
etanercept
solubl
human
receptor
abatacept
oral
gavag
vehicl
control
tofacitinib
jak
inhibitor
biolog
agent
use
shown
previous
activ
mice
chose
day
infect
initi
treatment
repres
time
point
first
peak
clinic
appar
foot
swell
mous
model
chikv
infect
fig
anim
follow
clinic
joint
swell
ipsilater
foot
viral
yield
differ
time
infect
treatment
treatment
tofacitinib
day
amelior
foot
swell
day
infect
point
peak
clinic
diseas
fig
c
f
mm
inject
control
versu
mm
p
mm
oral
control
versu
mm
tofacitinib
p
treatment
signific
effect
dose
test
experi
assess
system
local
impact
viral
burden
dmard
treatment
evalu
chikv
rna
level
day
serum
joint
tissu
remark
none
therapi
affect
viral
rna
level
right
ankl
left
ankl
day
day
infect
compar
control
fig
g
j
p
thu
tofacitinib
amelior
joint
periarticular
inflamm
mice
acut
phase
without
substant
alter
viral
burden
inflam
tissu
benefici
effect
block
cell
activ
consist
data
suggest
cell
contribut
immunopatholog
associ
chikv
arthriti
next
test
whether
combin
immunomodulatori
antivir
therapi
might
greater
benefici
effect
potent
neutral
human
antichikv
mab
previous
shown
protect
chikvinduc
lethal
immunocompromis
mice
even
administ
late
time
point
infect
administ
either
singl
dose
control
immunoglobulin
g
igg
antichikv
mab
neutral
antichikv
human
mab
antichikv
mab
fig
day
chikv
infect
wherea
either
antichikv
mab
partial
reduc
foot
swell
day
combin
complet
abolish
mm
versu
mm
p
rel
untreat
control
iggtreat
anim
fig
b
thu
antichikv
mab
therapi
initi
diseas
onset
partial
treat
acut
clinic
arthriti
associ
chikv
infect
combin
therapi
antichikv
mab
immunomodul
complet
resolv
clinic
diseas
mice
within
day
treatment
confirm
activ
antichikv
mab
model
assess
effect
viral
burden
treatment
antichikv
mab
alon
combin
day
elimin
infecti
viru
joint
infect
mice
within
day
observ
reduct
ipsilater
ankl
fig
p
reduct
contralater
ankl
fig
p
viral
burden
mice
treat
reduc
either
ipsilater
contralater
ankl
fig
although
infecti
chikv
detect
day
mous
model
chronic
phase
human
chikv
rna
persist
joint
tissu
month
persist
viral
rna
pathogenassoci
molecular
pattern
may
contribut
chikv
arthriti
test
whether
antichikv
mab
treatment
would
reduc
viral
rna
level
although
observ
reduct
viral
rna
level
ipsilater
foot
joint
p
extrem
joint
exhibit
reduct
viral
rna
day
infect
includ
contralater
ankl
ipsilater
wrist
fig
right
ankl
p
left
wrist
p
day
trend
toward
reduc
rna
distal
joint
tissu
anim
treat
antichikv
mab
although
attain
statist
signific
fig
p
collect
result
show
treatment
antichikv
mab
alon
combin
rapidli
elimin
infecti
viru
within
day
reduc
fail
clear
viral
rna
affect
tissu
begin
defin
basi
reduc
joint
swell
associ
treatment
analyz
effect
local
cytokin
chemokin
product
use
multiplex
assay
measur
cytokin
chemokin
level
ipsilater
foot
day
infect
anim
receiv
either
control
mab
antichikv
mab
combin
therapi
antichikv
mab
monotherapi
reduc
level
macrophag
inflammatori
histolog
analysi
joint
tissu
ipsilater
foot
reveal
reduc
leukocyt
infiltr
midfoot
joint
mice
receiv
combin
therapi
antichikv
mab
fig
f
yellow
arrow
moder
sever
synov
white
arrow
absent
mild
synov
next
quantit
number
inflammatori
cell
per
highpow
field
hpf
synovi
space
midfoot
combin
therapi
antichikv
mab
result
decreas
inflammatori
cell
infiltr
synovi
space
cell
per
hpf
control
group
cell
per
hpf
group
cell
per
hpf
antichikv
mab
group
p
p
respect
histolog
analysi
reveal
evid
bone
eros
proteoglycan
loss
effect
express
receptor
activ
nuclear
factor
ligand
rankl
osteoprotegerin
opg
fig
consist
role
modul
immun
cell
recruit
administr
day
infect
result
reduc
swell
day
day
fig
time
point
subcutan
edema
immun
cell
infiltr
observ
quantit
differ
immun
cell
infiltr
entir
foot
day
infect
analyz
flow
cytometri
antichikv
mab
treatment
affect
total
number
immun
cell
soft
tissu
ipsilater
foot
includ
skin
muscl
joint
treatment
combin
antichikv
mab
observ
threeto
fourfold
reduct
number
total
leukocyt
fig
b
p
markedli
reduc
number
inflammatori
monocyt
natur
killer
cell
cell
nearli
complet
absenc
cell
fig
b
g
contrast
treatment
antichikv
mab
alon
reduc
number
infiltr
cell
individu
leukocyt
subset
infect
foot
fig
g
block
cell
costimul
also
immunomodulatori
effect
antigenpres
cell
apc
human
use
studi
bind
murin
antigen
modul
apc
function
assess
apc
activ
day
infect
saw
differ
class
ii
major
histocompat
complex
marker
express
apc
isol
spleen
feet
control
mice
fig
test
whether
exert
therapeut
benefit
via
cell
compar
respons
control
mab
chikvinfect
wt
mice
latter
lack
cell
observ
benefici
effect
wt
anim
fig
c
p
mice
fig
b
c
p
reduc
swell
acut
chikv
infect
part
via
action
cell
worldwid
emerg
chikv
creat
need
identifi
treatment
epidemiolog
estim
suggest
million
suffer
acut
arthriti
least
peopl
western
hemispher
suffer
chronic
chikv
arthriti
reason
establish
therapi
use
treat
form
inflammatori
arthriti
exampl
rheumatoid
psoriat
arthriti
also
might
mitig
chikv
arthriti
experi
identifi
tofacitinib
candid
dmard
therapi
base
efficaci
acut
chikv
arthriti
mice
immunopatholog
like
contribut
pathogenesi
chikv
arthriti
previou
studi
use
anim
suggest
respons
depend
b
cell
anim
ipsilater
foot
swell
leukocyt
subset
infiltr
peripher
joint
chikvinfect
mice
primarili
consist
cell
inflammatori
monocyt
macrophag
block
cell
costimul
observ
reduc
infiltr
cell
inflammatori
monocyt
joint
infect
anim
although
suffici
elimin
clinic
diseas
complet
treatment
mice
effect
joint
swell
suggest
amelior
clinic
diseas
primarili
via
action
cell
find
consist
previou
studi
suggest
joint
swell
foot
anim
reduc
sever
complet
control
find
suggest
inhibitor
cell
function
also
might
limit
musculoskelet
diseas
associ
chikv
infect
teo
et
al
recent
demonstr
treatment
fingolimod
agonist
sphingosin
receptor
limit
infiltr
cell
chikvinfect
joint
adjac
muscl
mice
result
reduc
joint
swell
muscl
necrosi
previou
studi
show
mous
human
antivir
antibodi
could
prevent
chikv
arthriti
mice
administ
infect
protect
lethal
highli
immunocompromis
mice
found
treatment
wt
mice
day
chikv
infect
antivir
human
mab
reduc
elimin
joint
swell
although
infecti
viru
could
detect
joint
within
day
therapi
foot
swell
like
depend
multipl
factor
includ
synov
myositi
edema
result
product
proinflammatori
cytokin
antichikv
mab
elimin
infecti
viru
within
day
administr
reduc
foot
swell
without
alter
leukocyt
infiltr
joint
infect
anim
suggest
leukocyt
recruit
factor
affect
diseas
sever
model
local
cytokin
product
specif
compart
exampl
serum
muscl
joint
independ
may
affect
virusinduc
swell
edema
futur
histolog
studi
may
defin
better
precis
mechan
neutral
infecti
chikv
antivir
antibodi
amelior
foot
swell
type
interferon
ifn
respons
import
control
chikv
infect
mice
lack
type
ifn
signal
highli
vulner
dissemin
infect
chikv
succumb
within
day
due
high
level
viru
brain
spinal
cord
remark
treatment
tofacitinib
block
jakstat
signal
downstream
cytokin
receptor
reduc
clinic
diseas
without
ostens
effect
morbid
mortal
result
may
relat
pharmacodynam
tofacitinib
includ
short
halflif
tofacitinib
therapi
may
blunt
cytokin
product
andor
leukocyt
infiltr
without
enhanc
chikv
replic
nevertheless
tofacitinib
known
enhanc
risk
viral
infect
includ
varicella
zoster
viru
futur
combin
therapi
studi
tofacitinib
antivir
mab
may
warrant
anecdot
report
human
suggest
methotrex
may
effect
treatment
chikv
arthriti
studi
low
dose
methotrex
provid
benefit
acut
arthriti
remain
possibl
methotrex
would
show
greater
benefit
higher
dose
use
mous
model
ross
river
viru
arthriti
previous
reveal
exacerb
diseas
treatment
etanercept
wherea
uncontrol
studi
human
suggest
blockad
provid
benefit
patient
diagnos
chronic
rheumatolog
diseas
acut
chikv
infect
howev
import
note
patient
infect
chikv
may
develop
rheumatolog
diseas
sporad
coincident
chikv
infect
control
studi
mice
infect
chikv
find
benefit
etanercept
therapi
acut
chikv
arthriti
unabl
assess
chronic
diseas
histopatholog
absenc
frank
arthriti
chronic
phase
light
anim
model
result
anecdot
natur
previou
human
studi
seem
rigor
blind
placebocontrol
studi
human
patient
necessari
defin
dmard
therapi
may
safe
optim
patient
chronic
chikv
arthriti
chikv
relat
arthritogen
alphavirus
directli
invad
joint
leav
persist
viral
rna
joint
surround
tissu
even
absenc
detect
infecti
viru
previou
studi
found
chikvinfect
control
mice
exhibit
histopatholog
evid
chronic
arthriti
month
infect
although
mild
chronic
tenosynov
myositi
anim
could
readili
detect
viral
rna
joint
day
studi
suggest
persist
viral
rna
may
suffici
caus
clinic
appar
chronic
arthriti
mice
factor
must
contribut
pathogenesi
thu
remain
determin
whether
combin
treatment
antivir
antibodi
benefici
effect
chronic
chikv
arthriti
anim
model
sever
chronic
diseas
exampl
nonhuman
primat
may
requir
address
question
benefici
effect
antivir
antibodi
therapi
chikv
arthriti
must
interpret
caution
limit
mous
model
unlik
human
mice
natur
host
chikv
therefor
develop
sever
debilit
arthriti
commonli
observ
human
chikv
caus
less
sever
diseas
mice
remain
possibl
immunomodulatori
therapi
includ
may
even
deleteri
effect
human
concept
combin
antivir
immunomodulatori
therapi
uniqu
approach
treatment
infecti
diseas
nearcomplet
effect
combin
therapi
mous
model
acut
chikv
arthriti
implic
treatment
viral
infect
virusand
immunemedi
patholog
result
morbid
mortal
exampl
influenza
sever
acut
respiratori
syndrom
coronaviru
given
larg
number
clinic
avail
biolog
small
molecular
dmard
work
may
provid
greater
impetu
studi
test
combin
antivir
immunomodulatori
therapi
treatment
infecti
diseas
initi
studi
determin
whether
antiinflammatori
antivir
therapi
control
acut
chikv
arthriti
mice
initi
observ
treatment
antivir
antibodi
reduc
infecti
viral
burden
ipsilater
joint
therapi
diminish
recruit
cell
inflammatori
monocyt
well
accumul
proinflammatori
cytokin
subsequ
histolog
analysi
confirm
find
measur
viral
titer
rna
tissu
immunolog
paramet
includ
influx
specif
cell
subtyp
joint
surround
tissu
cytokin
level
sampl
size
end
point
select
basi
extens
experi
system
mice
ageand
sexmatch
group
histolog
analysi
perform
blind
fashion
initi
footpad
measur
perform
three
individu
unblind
fashion
howev
measur
treatment
reproduc
fourth
individu
perform
blind
assess
investig
blind
conduct
viru
tissu
burden
analysi
cytokin
measur
flow
cytometri
analysi
primari
data
supplementari
materi
tabl
anim
experi
perform
accord
approv
washington
univers
institut
anim
care
use
committe
guidelin
mous
infect
studi
perform
anim
biosafeti
level
laboratori
experi
perform
mice
mice
obtain
commerci
jackson
laboratori
recombin
strain
chikv
provid
higg
kansa
state
univers
gener
vitro
transcrib
cdna
previous
describ
week
age
mice
inocul
left
rear
footpad
ffu
strain
chikv
volum
infect
mice
monitor
daili
foot
swell
digit
calip
day
termin
experi
mice
sedat
ketaminexylazen
cocktail
euthan
perfus
via
intracardiac
inject
pb
tissu
inject
left
ankl
contralater
ankl
ipsilater
wrist
harvest
snapfrozen
dri
ice
store
process
rna
isol
serum
analysi
blood
collect
time
sacrific
centrifug
min
g
store
experi
serum
joint
tissu
isol
mice
day
infect
subsequ
analysi
focusform
assay
focusform
assay
perform
previous
describ
briefli
tissu
homogen
serum
incub
min
monolay
vero
cell
plate
cell
overlaid
wv
methylcellulos
modifi
eagl
media
supplement
fetal
bovin
serum
fb
plate
harvest
hour
later
fix
paraformaldehyd
pfa
pb
plate
incub
sequenti
chimer
ngml
horseradish
peroxidaseconjug
goat
antihuman
igg
pb
supplement
saponin
bovin
serum
albumin
chikvinfect
foci
visual
use
trueblu
peroxidas
substrat
kpl
quantit
immunospot
macroanalyz
cellular
technolog
ltd
rna
extract
tissu
use
rneasi
mini
kit
qiagen
quantiti
chikv
rna
determin
qrtpcr
use
taqman
rnatoct
kit
appli
biosystem
primerprob
set
two
microlit
isol
rna
analyz
qrtpcr
compar
standard
curv
gener
rna
isol
chikv
stock
determin
ffu
equival
human
mab
neutral
chikv
infect
describ
previous
antibodi
purifi
hybridoma
supernat
protein
g
affin
chromatographi
methotrex
abatacept
etanercept
obtain
center
advanc
medicin
rheumatolog
clinic
st
loui
mo
naproxen
sodium
methylprednisolon
acet
purchas
sigma
isotyp
control
antibodi
human
antiwest
nile
viru
antibodi
produc
chines
hamster
ovari
cell
purifi
protein
g
affin
chromatographi
infect
mice
sacrif
perfus
intracardiac
inject
pfa
indic
day
infect
infect
anklefoot
tissu
dissect
fix
pfapb
hour
follow
decalcif
acidfre
edta
day
decalcifi
tissu
embed
paraffin
section
stain
hematoxylin
eosin
h
e
evalu
light
microscopi
embed
section
stain
perform
musculoskelet
histolog
morphometri
core
washington
univers
school
medicin
sampl
visual
use
nikon
eclips
microscop
equip
qicam
camera
qimag
process
qcaptur
softwar
use
exposur
time
ankl
harvest
euthan
infect
mice
day
collect
pb
homogen
use
magna
lyser
roch
cytokin
level
measur
use
luminex
technolog
bioplex
pro
mous
cytokin
assay
millipor
mice
sacrif
day
inocul
perfus
pb
inocul
foot
disarticul
ankl
without
fractur
bone
cutan
subcutan
tissu
evert
still
attach
distal
foot
digit
digest
tissu
incub
hour
digest
buffer
rpmi
type
collagenas
data
analyz
graphpad
prism
softwar
viral
burden
analysi
cytokin
measur
number
infiltr
leukocyt
data
analyz
mannwhitney
test
anova
kruskalw
test
dunn
post
hoc
analysi
p
indic
statist
signific
differ
result
c
j
least
two
independ
experi
n
per
treatment
group
measur
data
day
n
viral
burden
analysi
day
data
repres
mean
c
f
median
g
j
sem
p
p
p
twoway
analysi
varianc
anova
analysi
swell
curv
mannwhitney
day
tofacitinib
analysi
kruskalw
dunn
post
hoc
analysi
day
inject
medic
viral
burden
analysi
mice
inocul
ffu
chikv
via
subcutan
rout
foot
swell
area
squar
millimet
day
day
mice
receiv
day
singl
intraperiton
inject
isotyp
control
antibodi
antichikv
mab
combin
antichikv
mab
data
pool
two
independ
experi
n
anim
per
group
b
repres
photograph
ipsilater
foot
swell
control
mab
combin
therapi
antichikv
mab
group
data
repres
mean
sem
p
p
twoway
anova
multipl
comparison
mice
inocul
ffu
chikv
via
subcutan
rout
mice
receiv
day
singl
intraperiton
inject
isotyp
control
antibodi
antichikv
mab
combin
antichikv
mab
infecti
viru
joint
serum
quantit
focusform
assay
day
infect
b
c
realtim
qrtpcr
analysi
viral
rna
level
ipsilater
left
contralater
right
ankl
left
wrist
day
infect
result
pool
two
independ
experi
n
per
treatment
group
viral
rna
data
n
focusform
assay
data
data
repres
median
sem
p
p
p
kruskalw
dunn
post
hoc
analysi
scale
bar
yellow
arrow
moder
sever
synov
white
arrow
absent
mild
synov
p
p
kruskalw
dunn
post
hoc
analysi
mice
inocul
ffu
chikv
via
subcutan
rout
mice
receiv
day
singl
intraperiton
inject
isotyp
control
antibodi
antichikv
mab
antichikv
mab
gate
strategi
show
subpopul
live
cell
includ
percentag
inflammatori
monocyt
follow
express
lower
panel
remain
cell
red
arrow
isol
feet
mice
treatment
group
b
g
total
number
isol
cell
feet
chikvinfect
mice
treatment
group
result
pool
two
independ
experi
mice
per
group
experi
data
repres
mean
sem
p
p
p
kruskalw
dunn
post
hoc
analysi
conduct
blind
fashion
result
pool
two
three
independ
experi
total
n
per
group
wt
anim
n
per
group
anim
data
repres
mean
sem
p
twoway
anova
multipl
comparison
swell
curv
mannwhitney
test
day
swell
